바카라 사이트What's New

News

2025/01/07
Nippon Kayaku Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
2024/11/01
Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advancedROS1-positive Non-Small Cell Lung Cancer.
2024/10/10
Annual update has been made to our Sustainability site.
2024/05/08
Received ‘AA’ for 바카라 사이트 first time in MSCI ESG Ratings
2023/12/15
NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDxTMIN JAPAN
2023/10/19
Updated information of sustainability
2023/10/18
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/09/25
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.PDF
2022/11/16
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibodyPDF
2021/06/30
New Late-Breaking Data at 바카라 사이트 American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 SeverityPDF
2020/07/06
Pict Leap Co., Ltd has developed “ Liquid Crystal Display Which Can Be Photographed By Infrared Camera ”PDF
2020/02/07
Pict Leap Co., Ltd has developed "32-inch off-grid outdoor display systemPDF
PageTop
Our Business
R&D
Stock Informati에볼루션 바카라
바카라 룰untry & Region
Stock Informati바카라
Integrated report